Show simple item record

dc.contributor.authorWestphalen, C. B.
dc.contributor.authorKrebs, Matthew G
dc.contributor.authorLe Tourneau, C.
dc.contributor.authorSokol, E. S.
dc.contributor.authorMaund, S. L.
dc.contributor.authorWilson, T. R.
dc.contributor.authorJin, D. X.
dc.contributor.authorNewberg, J. Y.
dc.contributor.authorFabrizio, D.
dc.contributor.authorVeronese, L.
dc.contributor.authorThomas, M
dc.contributor.authorde Braud, F.
dc.date.accessioned2021-08-17T12:22:44Z
dc.date.available2021-08-17T12:22:44Z
dc.date.issued2021en
dc.identifier.citationWestphalen CB, Krebs MG, Le Tourneau C, Sokol ES, Maund SL, Wilson TR, et al. Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population. npj Precis Onc. 2021 Jul 20;5(1).en
dc.identifier.pmid34285332en
dc.identifier.doi10.1038/s41698-021-00206-yen
dc.identifier.urihttp://hdl.handle.net/10541/624447
dc.description.abstractNeurotrophic tropomyosin receptor kinase (NTRK) gene fusions are rare oncogenic drivers in solid tumours. This study aimed to interrogate a large real-world database of comprehensive genomic profiling data to describe the genomic landscape and prevalence of NTRK gene fusions. NTRK fusion-positive tumours were identified from the FoundationCORE® database of >295,000 cancer patients. We investigated the prevalence and concomitant genomic landscape of NTRK fusions, predicted patient ancestry and compared the FoundationCORE cohort with entrectinib clinical trial cohorts (ALKA-372-001 [EudraCT 2012-000148-88]; STARTRK-1 [NCT02097810]; STARTRK-2 [NCT02568267]). Overall NTRK fusion-positive tumour prevalence was 0.30% among 45 cancers with 88 unique fusion partner pairs, of which 66% were previously unreported. Across all cases, prevalence was 0.28% and 1.34% in patients aged ≥18 and <18 years, respectively; prevalence was highest in patients <5 years (2.28%). The highest prevalence of NTRK fusions was observed in salivary gland tumours (2.62%). Presence of NTRK gene fusions did not correlate with other clinically actionable biomarkers; there was no co-occurrence with known oncogenic drivers in breast, or colorectal cancer (CRC). However, in CRC, NTRK fusion-positivity was associated with spontaneous microsatellite instability (MSI); in this MSI CRC subset, mutual exclusivity with BRAF mutations was observed. NTRK fusion-positive tumour types had similar frequencies in FoundationCORE and entrectinib clinical trials. NTRK gene fusion prevalence varied greatly by age, cancer type and histology. Interrogating large datasets drives better understanding of the characteristics of very rare molecular subgroups of cancer and allows identification of genomic patterns and previously unreported fusion partners not evident in smaller datasets.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1038/s41698-021-00206-yen
dc.titleGenomic context of NTRK1/2/3 fusion-positive tumours from a large real-world populationen
dc.typeArticleen
dc.contributor.departmentComprehensive Cancer Center Munich & Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.en
dc.identifier.journalNPJ Precision Oncologyen
dc.description.noteen]
refterms.dateFOA2021-08-18T09:50:21Z


Files in this item

Thumbnail
Name:
34285332.pdf
Size:
978.9Kb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record